Description : |
IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions. |
Catalog #: |
003-IGFBP6 |
Source: |
High-5 (BTI-Tn-5B1-4) Insect Cells |
Stability: |
The lyophilized protein is stable for a few weeks at room temperature, but best stored at -200C.
Reconstituted h-IGFBP-6 should be stored in working aliquots at -200C. |
Purity: |
Greater than 98% by SDS-PAGE and HPLC analyses. |
Endotoxin Level: |
Endotoxin level is less than 0.1 ng per μg (1EU/μg). |
Biological Activity: |
Determined by its ability to inhibit IGF-I or IGF-II induced proliferation of FDC-P1 cells. |
AA Sequence: |
RCPGCGQGVQ AGCPGGCVEE EDGGSPAEGC AEAEGCLRRE GQECGVYTPN CAPGLQCHPP KDDEAPLRAL LLGRGRCLPA RAPAVAEENP KESKPQAGTA RPQDVNRRDQ QRNPGTSTTP SQPNSAGVQD TEMGPCRRHL DSVLQQLQTE VYRGAQTLYV PNCDHRGFYR KRQCRSSQGQ RRGPCWCVDR MGKSLPGSPD GNGSSSCPTG SSG
|
PubMed Link : |
IGFBP-6 |
Usage: |
For research Purposes Only - Made using
a cell BTI-Tn-5B1-4 under license from the Boyce Thompson
Institute for Plant Research, Inc. Not for use in diagnostic
or therapeutic procedures.
|
Country of Origin: |
USA
|
